Bright Minds Biosciences (DRUG) stays a Strong Buy after Phase 2 BMB-101 seizure-reduction data; see 2026 catalysts, ...
BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...
FRIDAY, Dec. 5, 2025 (HealthDay News) -- Children referred to a first seizure clinic (FSC) see a neurologist epilepsy specialist within one week, according to a study presented at the annual meeting ...
Epilepsy is a common neurological disorder that affects millions of people worldwide. Characterized primarily by seizures, epilepsy can present in a variety of ways depending on the individual and the ...
The award recognizes Dr. Kuperman’s pioneering work in developing the Eysz™ HV Recorder, a novel device designed to standardize the hyperventilation procedure and collect objective video evidence to ...
BTIG initiated coverage on Bright Minds Biosciences Inc. (NASDAQ:DRUG), a clinical-stage company focused on neurological and psychiatric disorders. Investment in Bright Minds is based on the ...
Background: Pharmacoresistance to conventional antiseizure medications has been described in approximately 30% of the pediatric epileptic patients, making pharmacological management particularly ...
Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Epilepsy with myoclonic ...
Levetiracetam reduces tonic-clonic seizures by over 77% in clinical studies. Ethosuximide is highly effective for absence seizures, especially in children. Valproate remains the gold standard for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback